Pharmaceutical company Mallinckrodt is buying drugmaker Questcor for about $5.6 billion. Through the acquisition, Mallinckrodt will gain Questcor's lucrative drug Acthar Gel, which treats 19 different conditions that include autoimmune and inflammatory diseases. Sales of the drug jumped about 50% year-over-year in 2013, with Questcor generating about $760 million from it last year. Mallinckrodt said it expects the deal to add to adjusted earnings in 2014 and adjusted profit in 2014.
Stock quotes in this video: